Clinical Trials Directory

Trials / Completed

CompletedNCT01467037

Vaccine Effectiveness of RV1 in a Naïve Population

Status
Completed
Phase
Study type
Observational
Enrollment
374 (actual)
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre · Academic / Other
Sex
All
Age
8 Weeks – 3 Years
Healthy volunteers
Not accepted

Summary

Rotavirus (RV) is the leading cause of severe gastroenteritis (GE) in young children. The cumulative risk of GE hospitalizations and hospital stays of \< 24 hours is 1/25, which would amount to 13,600 Canadian children \< 5 years. The incidence of nosocomial RV infections is an average of 8/10,000 patient-days in children \< 5 years. An immunization program with a live-attenuated monovalent oral RV vaccine (RV1 - Rotarix® from GSK) will be implemented, free of charge, in the Province of Quebec in November 2011. To provide an accurate portrait of the disease and give critical information to the public health agencies as they struggle to control costs, we aim to evaluate the accuracy of surveillance for RV and other diseases with similar characteristics; estimate selection bias in passive laboratory-based surveillance; and estimate the agreement between surveillance time-series created from passive and active surveillance data sources.

Detailed description

In November 2011, Quebec implemented a publicly-funded RV1 vaccination program with its routine administration at 2 and 4 months of age. From February 1, 2012 - May 31, 2014, we conducted prospective, active surveillance for acute rotavirus gastroenteritis at The Montreal Children's Hospital and Centre Hospitalier Universitaire Sainte-Justine, located in Montreal, and Centre Hospitalier Universitaire de Sherbrooke, located in Sherbrooke. Active surveillance was approved by Research Ethics Boards at each hospital.

Conditions

Interventions

TypeNameDescription
OTHERNo intervention doneNot applicable because no intervention was done.

Timeline

Start date
2012-02-01
Primary completion
2014-12-01
Completion
2014-12-01
First posted
2011-11-08
Last updated
2016-04-19
Results posted
2016-01-29

Locations

3 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT01467037. Inclusion in this directory is not an endorsement.

Vaccine Effectiveness of RV1 in a Naïve Population (NCT01467037) · Clinical Trials Directory